One of the few bills moving through Congress with bipartisan support this spring would speed government approval of lower-cost generic copies of brand-name drugs. But one company, with help from an influential former congressman, is lobbying to protect its most lucrative brand-name product against generic competition and appears to have had some success in the House, potentially altering the bill to make it more favorable for the company.
